Skip to main content

Table 1 Patient characteristics

From: Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites

Characteristics Total cohort Pre-menopausal Post-menopausal p-value
  n = 109 n = 56 n = 53  
n (%) n (%) n (%)
Median age at assessment (years) 51 45 58 <0.0001
   Range 22 - 76 22-54 40 - 76  
Median Body Mass Index 24 24 24 0.44
   Range 17 - 43 17 - 34 18 - 29  
T-status (TNM)     0.73
   T1 48 (44%) 23 (41%) 25 (47%)  
   T2 27 (25%) 16 (29%) 11 (21%)  
   T3 2 (1.8%) 1 (1.8%) 1 (1.9%)  
   Unknown 32 (29%) 16 (29%) 16 (30%)  
N-status (TNM)     1.00
   N0 45 (41%) 24 (43%) 21 (40%)  
   N+ 49 (45%) 26 (46%) 23 (43%)  
   Unknown 15 (14%) 6 (11%) 9 (17%)  
AJCC stage (7th ed.)     0.87
   Stage I 26 (24%) 14 (25%) 12 (23%)  
   Stage IIa 32 (29%) 16 (29%) 16 (30%)  
   Stage IIb 7 (6%) 5 (9%) 2 (4%)  
   Stage IIIa 9 (8%) 4 (7%) 5 (9%)  
   Stage IIIb 0 0 0  
   Stage IIIc 6 (6%) 3 (5%) 3 (6%)  
   Unknown 29 (27%) 14 (25%) 15 (28%)  
Estrogen receptor     NA
   Positive 93 (85%) 50 (89%) 43 (81%)  
   Unknown 16 (15%) 6 (11%) 10 (19%)  
Progesterone receptor     1.00
   Positive 10 (9%) 5 (9%) 5 (9%)  
   Negative 83 (76%) 45 (80%) 38 (72%)  
   Unknown 16 (15%) 6 (11%) 10 (19%)  
HER2 status     1.00
   Positive 38 (35%) 20 (36%) 18 (34%)  
   Negative 55 (50%) 30 (54%) 25 (47%)  
   Unknown 16 (15%) 6 (11%) 10 (19%)  
Median duration of treatment (months) 9 9 9 0.73
   Range 2 - 70 2 - 59 3 - 70  
Tamoxifen (daily dose)     0.17
   10 mg 1 (1%) 1 (2%) 0 (0%)  
   20 mg 102 (94%) 50 (89%) 52 (98%)  
   40 mg 6 (6%) 5 (9%) 1 (2%)  
  1. T-status, Tumor status, N-status, Lymph node status, HER2, Human Epidermal growth factor Receptor 2.